Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Aspire-Lakewood Holdings, Inc.ASBPW · healthcare
GradeNonecomputable_factors_below_threshold: 5 of 14 inputs computable; 7 are required
Reliability0.76 AUCfailure model, filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate0.60% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size bandunder $12.5M assetstotal assets $1.3M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningslate filer, thin data, degenerate inputsnot computable: dilution, distress, fortress balance sheet
Inputs computable5 of 14
Graded fromfilings received through Apr 8, 2026184 days before the rescan; every figure keyed to the SEC receipt date
Last close$0.022026-07-13; market equity $0; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$0.02$0.04NovDecJanFebMarAprMayJunJulAugSepOct$0.01
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Mar 21, 2023nonen/aQ3
Mar 21, 2024nonen/aQ2
Apr 21, 2025nonen/aQ1

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 30, 2026; the document on sec.gov.

is an early-stage biopharmaceutical company. As a Delaware corporation formed in February 2025, the Company engages in the business of developing and marketing the disruptive technology for novel sublingual delivery mechanisms initially for known drugs. Prior to our Business Combination we were a privately held Puerto Rico corporation incorporated in September 2021. Our internet address is www.aspirebiolabs.com. expect to generate revenue through developing and marketing drugs and nutraceuticals using the technology for the novel sublingual delivery.

Warnings [top]

Late filer. found 1 NT 10-K/Q filings in the last eight quarters
Thin data. 5 of 14 grade factors are computable; minimum is 7
Degenerate inputs. latest revenue or assets are at or below the $100,000 validity floor[1-2]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 48.3
Gross profitability(0.01%)[1,3]32.2%96.63722025-12-31
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(2,678.8%)[1,4-6](6.6%)0.18112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 1
Solvency, sleeve percentile 97.5
Twelve-month failure probabilitynot computable0.07%
firm-wide XBRL shares cannot be assigned to one ticker class
Altman Z double-prime(199.10)[1,7-12](0.31)97.87562025-12-31
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
one or more required annual facts are missing
Current ratio0.17x[7-8]2.96x97.28392025-12-31
Growth and financing, sleeve percentile 99.9
Revenue growth, three-year compoundnot computable10.0%
four annual observations are required; found 1
Free cash flow growth, three-year compoundnot computable10.9%
four consecutive annual FCF observations are required; found 0
Reinvestment ratenot computable37.1%
one or more required annual facts are missing
Asset growth, three years(83.6%)[1,6,13-14]2.1%99.97042025-12-31
Net share issuance, one yearnot computable2.5%
firm-wide XBRL shares cannot be assigned to one ticker class

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-07-13 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month(49.8%)8.0%14hotter than 14 of 100 peers
Distance from 52-week high(69.6%)(31.4%)12closer to its high than 12 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yieldnot computable(1.0%)required accounting or market input is missing
Book value to pricenot computable0.28required accounting or market input is missing
Sales to pricenot computable0.31required accounting or market input is missing
Composite equity issuance, five yearsnot computable20.3%required accounting or market input is missing
Relative strength against the sector, log excess return(0.90)(0.14)14ahead of 14 of 100 peers

Inputs: EBIT -$19.4M; book equity $11.8M; sales $6,202; cash $12.2M[15].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(16,542.3%)✗ fail[4,6]
Operating cash flow above zero-$4.9M✗ fail[5]
Return on assets improved(16,535.8 pts)✗ fail[4,6,13,16]
Operating cash flow exceeds net income$19.6M✓ pass[4-5]
Long-term leverage felln/a[1,6,13]
Current ratio improved8.5 pts✓ pass[7-8,17-18]
No new shares issuedn/a
Gross margin improvedn/a[2-3]
Asset turnover improvedn/a[2,6,13]
Cash, filings, liquidity
Cash and equivalents$12.2M[19]
Operating cash flow, four quarters-$7.2M[5,19-23]
Months of runway20.3
Late filings, two years1
NT 10-K or NT 10-Q
Days since last periodic filing57
10-Q received Aug 13, 2026
Median daily dollar volume$0
63 sessions
Days since newest grade input184

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$1.3M2025-12-312026-04-0810-K/Afiling · viewer · series
2revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$6,2022025-12-312026-04-0810-K/Afiling · viewer · series
3gross profitus-gaap:GrossProfit-$1162025-12-312026-04-0810-K/Afiling · viewer · series
4net incomeus-gaap:NetIncomeLoss-$24.5M2025-12-312026-04-0810-K/Afiling · viewer · series
5operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$4.9M2025-12-312026-04-0810-K/Afiling · viewer · series
6assetsus-gaap:Assets$147,9892024-12-312026-04-0810-K/Afiling · viewer · series
7current assetsus-gaap:AssetsCurrent$1.3M2025-12-312026-04-0810-K/Afiling · viewer · series
8current liabilitiesus-gaap:LiabilitiesCurrent$7.6M2025-12-312026-04-0810-K/Afiling · viewer · series
9retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$27.3M2025-12-312026-04-0810-K/Afiling · viewer · series
10operating incomeus-gaap:OperatingIncomeLoss-$19.4M2025-12-312026-04-0810-K/Afiling · viewer · series
11book equityus-gaap:StockholdersEquity-$6.4M2025-12-312026-04-0810-K/Afiling · viewer · series
12liabilitiesus-gaap:Liabilities$7.7M2025-12-312026-04-0810-K/Afiling · viewer · series
13assetsus-gaap:Assets$20.0M2023-12-312025-04-0710-Kfiling · viewer · series
14assetsus-gaap:Assets$300.2M2022-12-312024-03-1110-Kfiling · viewer · series
15shares outstandingdei:EntityCommonStockSharesOutstanding1,402,5572026-08-072026-08-1310-Qfiling · viewer · series
16net incomeus-gaap:NetIncomeLoss-$1.3M2024-12-312026-04-0810-K/Afiling · viewer · series
17current assetsus-gaap:AssetsCurrent$147,9892024-12-312026-04-0810-K/Afiling · viewer · series
18current liabilitiesus-gaap:LiabilitiesCurrent$1.7M2024-12-312026-04-0810-K/Afiling · viewer · series
19cashus-gaap:CashAndCashEquivalentsAtCarryingValue$12.2M2026-06-302026-08-1310-Qfiling · viewer · series
20operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$5.2M2026-06-302026-08-1310-Qfiling · viewer · series
21operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$3.0M2026-03-312026-05-1510-Qfiling · viewer · series
22operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$4.0M2025-09-302025-11-1410-Q/Afiling · viewer · series
23operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$2.9M2025-06-302026-08-1310-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.